Immune checkpoint inhibitors (ICIs) have revolutionized the treatment of cancer, improving
outcomes in patients with advanced malignancies. The use of ICIs in clinical practice, and …

Immune checkpoint inhibitors (ICIs) are the standard of care for the treatment of several
cancers. While these immunotherapies have improved patient outcomes in many clinical …

Immune-related adverse events (irAEs) associated with immune checkpoint inhibitor (ICI)
therapy may vary substantially in their clinical presentation, including natural history …

Although immune checkpoint inhibitors (ICIs) have transformed the treatment landscape for
patients with many advanced malignancies, only 15–60% of patients respond, leaving a …

Immune checkpoint inhibitors (ICIS) such as inhibitors of CTLA-4, PD-1, and PD-L1, given as
monotherapy or combination therapy have emerged as effective treatment options for …

Abstract Purpose of Review The unleashing of the immune system in an effort to fight cancer
has proven to be an incredible advance in the war on cancer. However that breakthrough …

Background Immune-related adverse events (irAEs) are frequently reported during immune
checkpoint inhibitor (ICI) therapy and are associated with long-term outcomes. It is unknown …

Successful targeting and inhibition of the cytotoxic T-lymphocyte-associated antigen 4 and
programmed cell death-1 protein/programmed cell death ligand 1 immune checkpoint …

Immune checkpoint inhibitors (ICIs) are a class of drug that produces durable and sustained
anti-tumour responses in a wide variety of malignancies. The exponential rise in their use …

Importance Toxic effects of conventional chemotherapy and molecularly targeted cancer
therapies are generally well defined and occur at predictable points. By contrast, owing to …